Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,126 active trials259 approved drugs3,742 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,710 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06045260 | "Receptor Radionuclide Therapy With 177Lu-DOTATOC(LUFOR) | recruiting | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY |
| 1 |
| Aug 13, 2024 |
| clinicaltrials |
| NCT06341296 | Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer | recruiting | Phase 2 | 86 | West China HospitalOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06100497 | Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06543069 | Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM | recruiting | Phase 2 | 28 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06536959 | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS | recruiting | Phase 2 | 67 | Beijing 302 HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06537843 | Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia(VenCM) | recruiting | Phase 2 | 100 | Hospital Municipal São JoséOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06393816 | FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum(FIRST-NEC) | recruiting | Phase 2 | 80 | Centre Leon BerardOTHER | 2 | Aug 2, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05913427 | Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)(PESETA) | recruiting | Phase 2 | 80 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | recruiting | Phase 2 | 30 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06532084 | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen(SoraGVL) | recruiting | Phase 2 | 88 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06508099 | Vitamin A and D Supplementation in Allogeneic HCT(VitaStem) | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06528847 | Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma | recruiting | Phase 2 | 62 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04837859 | Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma(INDIE) | recruiting | Phase 2 | 120 | University of CologneOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06394674 | High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib | recruiting | Phase 2 | 84 | Changhai HospitalOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06518434 | A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients(CanHep) | recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06514313 | Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. | recruiting | Phase 2 | 110 | Yizhuo ZhangOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | recruiting | Phase 2 | 39 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06295926 | Serplulimab Combined With CCRT for LS-SCLC. | recruiting | Phase 2 | 96 | Peking Union Medical College HospitalOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06508216 | A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer(COMPASS-TNBC) | recruiting | Phase 1 / Phase 2 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06513234 | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | recruiting | Phase 2 | 45 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06236269 | HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan(ACROSS-TROP2) | recruiting | Phase 2 | 50 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT05844046 | Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients(MONTBLANC) | recruiting | Phase 2 | 83 | Enrico De ToniOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06413342 | Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 191 | Zhejiang Cancer HospitalOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05159245 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs(FINPROVE) | recruiting | Phase 2 | 250 | Helsinki University Central HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT05855811 | PREventing Second Cancers With DOSTARlimab(PREDOSTAR) | recruiting | Phase 2 | 400 | Centre Leon BerardOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06498622 | Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab | recruiting | Phase 2 | 45 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 12, 2024 | clinicaltrials |
| NCT06243393 | Sacituzumab Govitecan in Metastatic Colorectal Cancer(TROPHIT1) | recruiting | Phase 2 / Phase 3 | 80 | University Hospital HeidelbergOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05462236 | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | recruiting | Phase 2 | 120 | AUM Biosciences Pte LtdOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06491472 | Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer | recruiting | Phase 2 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06492421 | Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. | recruiting | Phase 2 | 90 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05636787 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients(TreoMel) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06301165 | TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 2 | 162 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06430736 | PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)(PRONTO) | recruiting | Phase 2 | 100 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05635487 | A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | recruiting | Phase 2 | 65 | Shengjing HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05876715 | LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma(LINNOVATE) | recruiting | Phase 1 / Phase 2 | 40 | ERLINDA M GORDONOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06487429 | Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer | recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05870475 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV(PV) | recruiting | Phase 2 | 94 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06483347 | Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT | recruiting | Phase 2 | 90 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485544 | Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial | recruiting | Phase 2 | 104 | Tang-Du HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06385730 | Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)(BLESS) | recruiting | Phase 2 | 60 | Shanghai Chest HospitalOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06482684 | CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma(CARMAN) | recruiting | Phase 2 | 150 | Christian Schmidt, MDOTHER | 1 | Jul 1, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 13, 2024source: clinicaltrials